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Abstract 
Pathological over-activity of the CA1 subfield of the human anterior hippocampus has 
been identified as a potential predictive marker for transition from a prodromal state 
to overt schizophrenia. Psychosis, in turn, is associated with elevated activity in the 
anterior subiculum, the hippocampal output stage directly activated by CA1. Over-
activity in these subfields may represent a useful endophenotype to guide 
translationally predictive preclinical models. To recreate this endophenotype and 
study its causal relation to deficits in the positive and cognitive symptom domains, we 
optogenetically activated excitatory neurons of the ventral hippocampus (vHPC; 
analogous to the human anterior hippocampus), targeting the ventral subiculum. 
Consistent with previous studies, we found that vHPC over-activity evokes 
hyperlocomotion, a rodent correlate of positive symptoms. vHPC activation also 
impaired performance on the spatial novelty preference (SNP) test of short-term 
memory, regardless of whether stimulation was applied during the encoding or 
retrieval stage of the task. Increasing dopamine transmission with amphetamine 
produced hyperlocomotion, but was not associated with SNP impairments. This 
suggests that short-term memory impairments resulting from hippocampal over-
activity likely arise independently of a hyperdopaminergic state, a finding that is 
consistent with the pharmaco-resistance of cognitive symptoms in patients. 
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Introduction 
The pathophysiology of schizophrenia is complex, involving a wide range of brain 
areas and neurotransmitter systems. The hippocampus is implicated as having a 
central role, since it displays a number of alterations in schizophrenia, including 
reduced volume, changes in organisation and cytoarchitecture1-4, and altered 
expression of synaptic proteins 2-5., and altered synaptic transmission 6-9. 
Hippocampal dysfunction is also evident in imaging data from patients with 
schizophrenia, who show over-activation of the hippocampus, both at rest 10-13, and 
during tasks requiring minimal cognitive load 14,15. Notably, such over-activity of 
anterior CA1 and subiculum has been correlated with the severity of positive, 
negative and, more recently, cognitive symptoms of schizophrenia10,11,16. It is not 
clear, however, if these symptoms are directly caused by over-activity of 
hippocampal output. 
Altered hippocampal structure and function, including reduced hippocampal volume17 
and anterior hippocampal over-activity11 have also been reported in individuals at 
high-risk of developing schizophrenia. Evidence that hippocampal over-activity 
spreads from the CA1 region to the subiculum during the transition from the 
prodromal to the psychotic state16 suggests that altered hippocampal function reflects 
a primary stage of impairment in schizophrenia, and that therapeutic intervention to 
regulate hippocampal activity could be effective in preventing disease 
progression16,18,19. Hippocampal over-activity may therefore represent a crucial 
biomarker20, and elucidating the mechanisms whereby this activity contributes to the 
different symptom domains may be a critical step in drug discovery. 
The rodent hippocampal formation, including the ventral hippocampus (vHPC; 
analogous to the human anterior hippocampus), and particularly the ventral 
subiculum (vSUB), can modulate the activity of dopaminergic neurons in the ventral 
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tegmental area (VTA)21-25, and increase dopamine release in the nucleus accumbens 
(NAc)26-30. These changes to the midbrain dopaminergic system are also associated 
with hyperlocomotion 31,32, a putative rodent correlate of positive symptoms in 
rodents33. It has therefore been proposed that hippocampal over-activity contributes 
to the hyperdopaminergic state underlying the emergence of positive symptoms of 
schizophrenia34,35. In support of this hypothesis, activation of the vHPC (with 
electrical or chemical stimulation) has previously been shown to produce rodent 
correlates of positive symptoms in translational paradigms such as pre-pulse 
inhibition and latent inhibition 36,37. It has also been shown, in a developmental rat 
model of schizophrenia (methylazoxymethanol acetate), that the altered activity of 
VTA dopaminergic neurons and increased locomotor responses to amphetamine can 
be normalized by pharmacological inhibition of the vHPC38.  
Genetically and spatially targeted manipulation of neural circuits using optogenetics 
provides a novel class of rodent models of psychiatric diseases, which are more 
specific and mechanistically defined than previous pharmacological or transgenic 
models39. With this approach, physiological endophenotypes (i.e. abnormal circuit 
activity) observed in patients can be precisely recreated in rodents, and can be used 
to test whether such abnormal physiological activity plays a causal role in specific 
symptoms. If so, they represent a biomarker in preclinical drug screening39 and 
clinical monitoring of therapeutic efficacy. Furthermore, this approach allows 
temporal control not afforded by previous techniques. For example, in contrast to 
chemical stimulation, optogenetics can model over-activation during specific epochs 
of behavioural tasks. Additionally, unlike electrical stimulation, manipulations can be 
targeted to the soma of specific cell types, leaving fibres of passage unaffected. 
Using such precise tools of control, the targeted re-creation of endophenotypes of 
abnormal neurophysiological activity observed in patients might be a promising novel 
route to derive optogenetic rodent models with relevance to psychiatric disorders40. 
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This approach has, however, not yet been widely adopted in the context of 
schizophrenia41-44. 
To explore the mechanistic link between increased hippocampal output, 
dopaminergic regulation, and cognitive impairment, we aimed to optogenetically re-
create the endophenotype of anterior hippocampal over-activity observed in patients. 
The effects of electrical stimulation and pharmacological activation of the 
hippocampus in rodents are thought to be mediated by increased activity of 
excitatory projection neurons at the vHPC output stage – the vSUB 23-25,35. Therefore, 
we aimed to selectively activate excitatory neurons of the vSUB, and assess the 
effects of this manipulation on novelty-induced hyperlocomotion and hippocampus-
dependent short-term memory performance (assessed with the Y-maze spatial 
novelty preference task 45). While the mechanisms whereby increased hippocampal 
activity leads to hyperlocomotion in rodents have been extensively studied 29,46,47, the 
link between hippocampal over-activity and cognitive impairment are less clear48.  
Results 
Histology 
To allow activation of excitatory vSUB output neurons, we injected the optogenetic 
activator Chronos bilaterally into the vHPC of CamKIIα-Cre mice, and implanted optic 
fibres for light delivery. Optic fibre tracts were not visible in their entirety in the sliced 
tissue; therefore the precise location of the tips of the optic fibres could not be 
determined in every experimental animal. Additional animals in which optic fibres 
were coated in fluorescent DiI and implanted at the same coordinates demonstrated 
that the placements effectively targeted light towards the vSUB (see Fig. 1a). 
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Furthermore, in cases where partial tracts were visible in experimental animals, the 
AP coordinates and ML locations were entirely consistent with these data.   
All Chronos-transfected animals meeting the optogenetic stimulation calibration 
criteria (see methods; n = 18) had expression in the targeted vSUB area in the 
stimulated hemisphere (Fig. 1a; left panel, Fig. 1b). Many animals also had some 
strong expression in parts of the adjacent ventral CA1 subfield (16/18) and/or weak 
expression in the ventral DG (14/18) and CA3 (9/18). Viral expression outside the 
vHPC was seen in only 4/20 animals, where weak expression was also evident in 
parts of the amygdalopiriform transition area, posteromedial cortical amygdaloid 
area, and the posteromedial amygdalohippocampal area, which are adjacent to the 
vSUB. Given the placement of the optical fibre just above vSUB (see Fig. 1a; right 
panel), the low light powers used, and weak offsite expression, it is unlikely that the 
light effectively stimulated transfected subfields outside of the vSUB/vCA1. 
Nevertheless, we refer to our manipulation as vHPC (not vSUB) stimulation, to 
acknowledge the potential contribution of induced overactivity in adjacent 
hippocampal subfields to the observed behavioural effects.  
Behaviour 
Calibration of optical stimulation intensity. We first calibrated stimulation levels in 
the Chronos group to determine the level of stimulation just sufficient to produce 
hyperlocomotion via either one of the bilaterally implanted optic fibres (i.e. 
hemispheres, see Methods). The individually determined power values (mean power 
= 3.4 mW, range: 2-5 mW) and the unilateral stimulation configuration were kept for 
the remainder of the test battery to minimize the risk of optogenetic over-stimulation 
or the induction of seizures. Animals exhibiting seizures (n = 4), or failing to show 
hyper-locomotion with optical stimulation at 5 mW in either hemisphere (n = 7) during 
calibration were excluded from all subsequent tests. Our observations indicated that 
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susceptibility to seizures was likely due to strong off-target expression in the dentate 
gyrus and/or CA3 seen in some mice. 
Optogenetic stimulation of the vHPC induces hyperlocomotion. After calibration, 
we confirmed that the same stimulation intensity elicited hyperlocomotion in a novel 
open field. Locomotor activity (distance travelled) was measured for 30 minutes and 
scored in 3-min bins, with 3 minutes of stimulation starting at minute 15. We 
calculated the distance travelled during the stimulation block as a percentage of the 
average distance travelled during the baseline period (previous 3 bins; 3 min each; 
from min 6) to assess hyperlocomotion. Again, we found that the change in 
locomotion during optogenetic stimulation in Chronos-transfected animals was 
significantly higher than in GFP controls (Fig. 1c, d; stimulation as % of baseline: 
D(28) = 1.59, p = 0.01; Kolmogorov-Smirnov Z Test; n = 14 Chronos, 16 Controls). 
The relative increase in locomotion during the stimulation period was significantly 
greater than baseline (100 %) in Chronos animals (p = 0.004; One-Sample Wilcoxon 
Sign Rank Test), but not in GFP-transfected controls (p = 0.92; One-Sample 
Wilcoxon Sign Rank Test). The effects of stimulation on locomotion showed a non-
significant trend to increase over each minute of the 3 min stimulation in Chronos 
animals (see Fig. 1c, inset; χ2(2) = 2.71, p = 0.26; Related-Samples Friedman’s). 
Additionally, we found that locomotion relative to baseline was significantly higher in 
the Chronos group than in controls during the 3 min block after stimulation (Fig. 1d; 
minutes 18-21; first post-stim block as % of baseline: D(28) = 1.39, p = 0.04, 
Kolmogorov-Smirnov Z Test). As unilateral manipulations may produce turning 
behaviour 49, we also assessed rotations during the optogenetic stimulation. Chronos 
animals turned significantly more than GFP-transfected controls during the 
stimulation (3 min; t (28) = 2.32, p = 0.03; number of turns: Chronos = 8.4 ± 1.1, 
GFP= 5.6 ± 0.6; Mean ± SEM). However, there were no group differences in the 
percentage of contralateral turns during stimulation (% total rotations; D(28) = 0.66, p 
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= 0.78, Kolmogorov-Smirnov Z Test), and there was no evidence of bias for turning 
towards the contralateral side (% contralateral turns: Chronos = 49.7 ± 6.8 %, GFP= 
56.3 ± 6.6 %; Mean ± SEM). It is likely that increased rotations in the Chronos group 
reflect the general increase in locomotor activity resulting from vHPC stimulation, 
rather than an induction of circling.   
Role of dopamine D2-receptors in mediating hyperlocomotion induced by 
optogenetic stimulation of vHPC. According to a prominent circuit model of 
schizophrenia21 the primary, albeit indirect, downstream effect of an over-active 
vHPC is increased burst firing of dopaminergic neurons in the VTA, which innervate 
the NAc. This leads to the prediction that the transient increase in locomotion caused 
by optogenetic stimulation of the vHPC (Fig. 1c, d) should be eliminated by D2R-
antagonism. To test this hypothesis, we injected raclopride, a selective and potent 
D2/3-antagonist (Rac; 1 mg/kg), or vehicle (Veh) one hour before testing the effect of 
optogenetic vSUB stimulation (Fig. 1e, f). We observed a strong suppression of 
baseline locomotion by raclopride, which confounds further analysis of relative 
locomotor activity during stimulation normalized to baseline locomotion (see Fig. 1f 
for relative values calculated as for Experiment 1).  
Instead, we assessed the absolute values of locomotion using a 3-way ANOVA with 
repeated measures of phase (baseline vs. stimulation) and drug (vehicle vs. 
raclopride), and a between-subject factor of group (Chronos vs. GFP. Relative to 
vehicle, raclopride strongly suppressed locomotion in both groups throughout testing, 
as evidenced by a main effect of drug and the lack of significant drug x group and 
drug x phase interactions (see Fig. 1e; drug: F(1,26) = 51.58, p < 0.001; drug x 
group: F(1,26) = 0.90, p = 0.35; drug x phase: F (1, 26) = 0.24, p = 0.63).  There 
was no overall effect of group (F (1, 26) = 1.08, p = 0.31), but a significant main 
effect of phase (F(1, 26) = 9.86, p = 0.004), indicating a locomotor-increasing effect 
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of the optical stimulation irrespective of drug and group (see Fig. 1e-h). Furthermore, 
the group x phase interaction (F (1, 26) = 10.46, p = 0.003), and group x phase x 
drug interactions were both significant (F (1, 26) = 8.63, p = 0.007).  
To further explore these interactions, separate 2-way repeated-measures ANOVAs 
analysing the effect of drug and test phase were conducted within each group (Fig. 
1g, h). In the Chronos group, there was a significant effect of phase and drug 
(phase: F(1,11) = 8.03, p = 0.02; drug: F(1, 11) = 41.16, p < 0.001), but no 
significant drug x phase interaction (F(1,11) = 1.61, p = 0.23), implying that raclopride 
reduced baseline locomotion throughout, but was ineffective against the laser-
induced increase of locomotion (Fig. 1h). In contrast, in the GFP controls, there was 
a significant drug x phase interaction (F (1, 15) = 12.73, p = 0.003), but, in turn, no 
main effect of phase (F (1, 15) = 0.05, p = 0.83), while a significant effect of drug (F 
(1, 15) = 18.60, p = 0.001) remained. This implies (see Fig. 1g) that, although the 
stimulation did not increase locomotion in the GFP-group in general, there was a 
stimulation-induced increase exclusively in the raclopride condition. This may be due 
to reinvigoration of exploration by the presentation of a prominent visual cue (the 
laser light) on a low background level of locomotion. An additional 2-way group x 
phase ANOVA within the raclopride condition revealed a significant effect of phase (F 
(1, 26) = 7.98, p = 0.009), but no main effect of group (F (1, 26) = 0.26, p = 0.62), or 
group x phase interaction (F (1, 26) = 1.87, p = 0.18). This indicates that the 
stimulation-induced increase in locomotion in the raclopride-treated Chronos group 
was not significantly greater than the stimulation-related increase seen in raclopride-
treated GFP controls (Fig. 1i). Together, these results indicate that raclopride failed 
to prevent the specific increase of locomotion during the stimulation period, despite 
effective suppression of baseline locomotion. However, as there was no significant 
group difference under raclopride, it is possible that this raclopride-resistant 
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locomotor increase reflects non-specific arousal caused by the laser pulses, rather 
than a direct optogenetic effect. 
Optogenetic stimulation of vHPC alters spatial novelty preference. We next 
used a task assessing hippocampus-dependent short-term memory45 to investigate 
the effect of vHPC over-activity on cognitive function. We tested spatial novelty 
preference in the Y-maze following optogenetic activation of the vHPC during 
different phases of the task (see Fig. 2a, b). We stimulated the vHPC either during 
the sample phase (5 min), the ITI (1 min), the test phase (2 min), or throughout both 
the ITI and the subsequent test phase (3 min). Novelty-preference was calculated as 
the ratio of time spent in the novel arm divided by time spent in both choice arms 
combined (excluding the start arm). Locomotion was assessed by distance travelled 
(m) and was converted to speed (m/min) to normalize data relative to the duration of 
each phase of testing.  
We verified that Chronos animals (n = 10) showed hyperlocomotion relative to GFP 
controls (n = 16) during the phase of the test in which stimulation was applied (Fig. 
2c; Sample: t(24) = 4.54, p < 0.001; Test: D(24) = 1.43, p = 0.034; ITI + Test: D(24) 
= 1.36, p = 0.048; activity levels were not tracked in the holding cage and therefore 
locomotor data for the ITI-only condition are not available). This hyperactivity 
confirmed that optogenetic stimulation was effective. 
Optogenetic vHPC stimulation did not affect the time spent in both goal arms 
combined during the test phase (NOV+FAM; Sample: t(24) = -0.43, p = 0.67; ITI: 
t(24) = 0.52, p = 0.61; Test: D(24) 0.78, p = 0.59; ITI + Test: t(24) = 0.679, p = 0.50). 
However, vHPC stimulation significantly impaired spatial novelty preference when 
conducting an ANOVA with stimulation condition (ITI + Test, ITI, Test, Sample) as a 
repeated measure in those animals where data was available for all stimulation 
conditions (Fig. 2d; n = 10 Chronos, 16 GFP). There was a significant main effect of 
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group (GFP vs Chronos; F(1,24) = 6.32, p = 0.019), but no significant effect of 
stimulation condition (F(3,72) = 0.31, p = 0.819), and no interaction (F(3,72) = 1.36, p 
= 0.262), indicating that stimulation of the vHPC during any stage of testing in 
Chronos animals impaired task performance to some degree (Fig. 2b, d, e). 
Importantly, SNP impairments were not due to insufficient exploration during the 
sample phase, as the time spent in the open goal arm during the sample phase did 
not differ between groups for any of the stimulation paradigms (Sample: t(24) = -
1.38, p = 0.18; ITI + Test: t(24) = 1.02, p = 0.32; ITI: D(24) = 0.37, p = 1.0; Test: 
t(24) = -0.2, p = 0.85).  
Optogenetic stimulation of the vHPC does not alter anxiety or induce place 
preference. Optogenetic induction of vHPC over-activity impaired SNP, implying an 
impairment of short-term memory. However, novelty-preference could also be altered 
due to emotional or motivational changes, rather than cognitive deficits. Firstly, 
activation of the vHPC could reduce the preference for novel places by altering the 
balance between exploratory drive and unconditioned anxiety23, since manipulations 
of the ventral hippocampus may affect anxiety 50-53. If vHPC activation increases 
anxiety, this could compete with the drive towards exploration of the novel arm during 
the novelty preference test. A second potential confound is that the optogenetic 
stimulation itself, through downstream effects on the dopaminergic system54, might 
be perceived as rewarding, and therefore induce a place preference (PP) for the 
location in which the optogenetic stimulation occurred (i.e. the familiar arm when 
stimulated during the sample trial). This preference would then conflict with the drive 
to explore the novel arm for the sample-only stimulation condition. 
We assessed both these potential explanations. First, we used the elevated plus- 
maze to measure exploration/anxiety balance and stimulated the vHPC starting 30 s 
before placement on the maze, and continuing for the first half (2.5 min) of maze 
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exploration (see Fig. 3a). Again, we successfully induced hyperlocomotion compared 
to GFP-controls during the stimulation period (Fig. 3b; t(25) = 3.45, p = 0.002; n = 13 
Chronos, 14 GFP). However, the preference for the time spent in the open arms 
during stimulation was not altered in the Chronos group compared to controls (Fig. 
3c; D(25) = 0.49, p = 0.973; Kolmogorov-Smirnov Z Test).  
Second, to test for the possibility of an optogenetic induction of a place preference 
using the same exposure (5 min) and ITI times (1 min) as the Y-Maze task, we 
adapted this paradigm to resemble a conditioned place preference paradigm (see 
Fig. 3d). In contrast to the SNP test, mice sampled both goal arms separately before 
the test phase, while only exploration of the second goal arm was accompanied by 
optogenetic stimulation of the vHPC. Again, we could induce hyperlocomotion in 
Chronos animals selectively during the optogenetic stimulation phase compared to 
controls (Fig. 3e; Non-Stim: t(27) = -0.10, p = 0.92: n = 15 Chronos, 14 GFP; Stim: 
t(25) = 2.08, p = 0.048: n = 13 Chronos, 14 GFP; Test: t(27) = -0.55, p = 0.59: n = 15 
Chronos, 14 GFP). Nevertheless, there was no evidence of a subsequent preference 
for the arm that was paired with stimulation in Chronos animals (preference vs 0.5; 
t(14) = -1.03, p = 0.32), and no significant difference between the groups (Fig. 3f; t 
(1, 27) = -0.52, p = 0.606; n = 15 Chronos, 14 GFP).  
Note, however, that in this paradigm, it was not possible to counterbalance the order 
of stimulation vs no stimulation due to potential carry-over effects of optogenetic 
stimulation. (i.e. stimulation during the first sample would also potentially effect the 
second sample), as hyperlocomotion persisted for at least 3 min after stimulation; 
(see Fig. 1b, c). Counter-balancing the order of stimulation would have additionally 
separated the stimulation from the test phase by delays longer than those used in the 
Y-maze task.  
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Nevertheless, it is therefore possible that the lack of any effect results from 
competition between place preference (preferred exploration of the stimulated arm), 
and recency, which would drive preference for the non-stimulated arm (i.e. the less 
recently experienced arm). To address this issue, we conducted a long-term place 
preference task during which the sample phases were separated by 2 hours, 
allowing for counterbalancing of the stimulation/no stimulation order (see Fig. 3g). 
Note that Chronos animals only showed a trend towards hyperlocomotion during the 
stimulation in this case (Fig. 3h; D(28) = 1.27, p = 0.08; Kolmogorov-Smirnov Z Test). 
However, in the test phase (24 h later), there was still no evidence of a preference for 
the stimulated chamber of the apparatus in Chronos animals (preference ratio vs 0.5; 
t(14) = 0.420, p = 0.68), and no significant group difference (Fig. 3i; D(28) = 0.85, p = 
0.459; Kolmogorov-Smirnov Z Test, n = 14 Chronos, 16 GFP).  Together, these 
results indicate that optogenetic stimulation does not impair novelty preference by 
increasing anxiety or the rewarding value associated with the stimulated arm.   
Increased dopamine transmission does not impair spatial novelty preference. 
Given that optogenetic vHPC stimulation impaired spatial short-term memory during 
the SNP task, and that the hyperactivity induced by vHPC stimulation is associated 
with increased dopaminergic transmission 26,27,31, we asked whether increased 
dopamine transmission alone is sufficient to alter SNP. We assessed SNP in control 
mice injected with the pro-dopaminergic drug amphetamine (Fig. 4a; Amph), at a 
dose known to produce robust locomotor hyperactivity 55. As expected, amphetamine 
(2.5 mg/kg) led to strong hyperlocomotion relative to vehicle-injected mice (Veh) 
during both the sample and test phases of the task (Fig. 4b; sample: t (21) = -5.63, p 
< 0.001; test:  t (13.79) = -8.62, p < 0.001). Amphetamine administration did not alter 
the time spent exploring the goal arm during the sample phase (t (21) = -1.43, p = 
0.17), or the time spent in both goal arms combined during the test phase (Novel + 
Familiar; t (21) = 0.37, p = 0.71). Importantly, amphetamine-treated mice showed a 
 
 
14
similar novel arm preference to vehicle-injected controls (Fig. 4c; t(15.68) = 0.06, p = 
0.95). Furthermore, preference ratios for both groups were significantly above 
chance (Veh: t(10) = 4.51, p = 0.001; Amph: t(11) = 8.17, p < 0.001), i.e. both groups 
spent significantly more time exploring the novel compared to the familiar arm, 
suggesting that they had intact short-term memory for the arm visited in the sample 
phase. 
Discussion 
Here we aimed to model schizophrenia-related over-activity of ventral hippocampal 
(vHPC) output by using optogenetics to selectively activate excitatory projection 
neurons of the vHPC, specifically targeting the ventral subiculum (vSUB). In addition 
to high spatial, temporal and genetic resolution, allowing more controlled modelling of 
vHPC hyperactivity than earlier approaches (chemical/electrical stimulation), the 
calibration of stimulation power for each animal allows for a similar level of activation 
across animals. While the applied stimulation frequency of 20 Hz probably does not 
exactly recapitulate the hippocampal hyperactivity seen in patients and may not 
represent endogenously produced spike activity, it is known to effectively increase 
dopamine transmission in the nucleus accumbens (NAc) and locomotor activity in 
rodents when used for electrical vHPC stimulation 28-30. It therefore effectively models 
the hypothesized hyperdopaminergic downstream effects of such changes in the 
anterior HPC in patients. We found that optogenetic induction of vHPC over-activity 
causes robust hyperlocomotion and a hippocampus-dependent memory deficit; 
putative rodent correlates of positive and cognitive symptoms of schizophrenia, 
respectively. We also show that these features are likely dissociable, as only the 
induction of hyperlocomotion is mimicked by elevating dopaminergic signalling.  
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The locomotion-promoting effect of the previously described pharmacological or 
electrical stimulation of the vHPC 22,29,47 has been proposed to result from increased 
firing of VTA dopamine neurons, and subsequent increases in dopamine release in 
the NAc 21,26,38. D2 receptors in the NAc are known to be necessary for mediating 
spontaneous locomotion56. To establish whether such a D2-dependent mechanism 
also underlies the hyperlocomotion produced by optogenetic stimulation of the vHPC, 
we tested the effect of the D2-antagonist raclopride on optogenetically-induced 
hyperlocomotion. Raclopride did not significantly decrease the effect of optogenetic 
stimulation on relative levels of locomotion, akin to hyperlocomotion produced by 
electrical vHPC stimulation in rats 29. However, we also observed an increase in 
locomotion during stimulation in the GFP control group treated with raclopride, which 
might have resulted from the salient visual stimulus of the laser light re-invigorating 
exploration in these partially sedated animals. Consequently, the group comparison 
within the raclopride condition revealed statistically similar stimulation-induced 
increases in locomotion in both groups, raising the possibility that the raclopride-
resistant increase in the Chronos group was induced non-specifically by the laser 
light rather than optogenetically.  
We also found that optogenetic stimulation of the vHPC impaired performance on a 
test of hippocampus-dependent short-term memory, suggesting that hippocampal 
over-activity in rodents may lead to phenotypes that are potentially relevant to the 
cognitive symptoms of schizophrenia. Furthermore, these differences in SNP are not 
explained by alterations in anxiety or potential rewarding effects of vHPC optogenetic 
stimulation. A previous study found that silencing hippocampal projections to the 
medial prefrontal cortex specifically during the encoding, but not the retrieval phase 
of a spatial short-term memory task reduced performance 57. In contrast, in our study, 
the lack of an interaction between group and stimulation phase indicated that 
activation of the vHPC is detrimental to spatial short-term memory regardless of 
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whether stimulation occurs during the encoding or retrieval phases of the task. This 
could arise from disruptions of state-dependent memory processes, whereby 
performance is impaired as a result of changes in behavioural state between 
encoding and retrieval. However, given that the effects of optogenetic stimulation 
(and presumably the associated behavioural state) were found to outlast the 
stimulation period on a timescale of several minutes (see Fig 1b, c), the impairment 
in animals stimulated during the sample phase only would argue against this 
explanation.  
An important question relates to the mechanism underlying the cognitive impairment. 
In particular, we addressed whether the short-term memory impairment induced by 
over-activation of the vHPC could result from the well-described induction of a 
hyperdopaminergic state. It was not possible to evaluate the role of dopamine 
signalling in this study using the same pharmacological approach that was used 
previously in the hyperlocomotion test, as raclopride was found to decrease baseline 
locomotion in all animals, and exploration is critical for the novelty preference task. 
Therefore, we did the reverse experiment, and tested whether pharmacologically 
increasing dopamine signalling alone was sufficient to induce impairments in the Y-
maze SNP task. We found that wild-type mice injected with a dose of amphetamine 
sufficient to produce robust hyperlocomotion did not show short-term memory 
impairments. This suggests that the cognitive impairment induced by vHPC 
hyperactivity is likely independent of increased dopamine transmission. Admittedly, 
this conclusion is indirect, as it is unclear if systemic amphetamine at the given dose 
reproduces the effect of optogenetic vHPC stimulation on dopamine 
neurotransmission in terms of magnitude, time course, and regional specificity. 
Nevertheless, the present results do show that an impairment in SNP cannot simply 
arise from an elevation of dopamine signalling, or locomotor hyperactivity alone.  
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This model of optogenetic over-activation provides a valuable tool to study which 
schizophrenia-related deficits and symptom domains may be caused by an 
overactive hippocampus, and to what extent elevated dopamine signalling is 
involved, or indeed, other downstream brain structures. Manipulations of the dorsal 
HPC, the nucleus reuniens of the thalamus, and the mPFC have been shown to alter 
performance on working memory tasks 44,58-60, and the hyperactivity of the vHPC 
might influence short-term memory through direct projections via these regions, 
independent of polysynaptic loops through the dopamine system 61,62. This would 
support our claim that the dopamine-related phenotypes and the memory 
impairments induced by vHPC stimulation are dissociable. For example, in a direct 
comparison of the effects of pharmacological or electrical stimulation of the dorsal vs. 
the ventral hippocampus, only the latter resulted in increased activity of the 
mesolimbic dopamine system and produced phenotypes linked to the positive 
symptom domain 37,63. This anatomical separation of downstream effects of vHPC 
hyperactivity is consistent with the observation that antipsychotics, which act 
primarily on the dopamine system, are largely ineffective against cognitive symptoms 
of schizophrenia. 
 Materials and Methods 
Surgery 
To allow activation of excitatory vSUB output neurons, we exploited the fast kinetics 
and high apparent light sensitivity of the optogenetic activator Chronos (ChR90), with 
GFP as a reporter protein 64. Twenty-nine adult male CamKIIα-Cre mice on a 
C57BL/6 background (B6.Cg-Tg(Camk2a-cre)T29-1Stl/J, Jackson Laboratories 
strain # 005359, MA, USA) were transfected bilaterally with AAV8-EF1α-FLEX-
Chronos-GFP (5.1 * 1012 IU/ml) and 16 male littermates with AAV5-hSyn-FLEX-GFP 
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(3.4 * 1012 IU/ml), targeting the vSUB using an angle of 25 (right hemisphere) or 23 
(left hemisphere) degrees towards the midline at AP-3.3 mm, ML+/- 4.5 mm, and 3.3 
mm distance from pia (Fig. 1a, left). Viral vector suspensions (80 nl) were infused 
(100 nl/min) through Hamilton syringes with bevelled needles (34G), with the bevel 
facing laterally. The needle was left for 10 min before withdrawal to reduce backflow. 
Viral vectors were obtained from the University of North Carolina viral vector core. 
Optic fibres (1.25mm ferrule diameter; Thorlabs, UK) cut to a length of 5.5 – 6 mm, 
were implanted bilaterally at AP -3.3 mm, ML +/-2.8 mm from bregma and 3.9 mm 
below pia and fixed in place with dental cement and jewellers screws (Fig. 1a, right; 
Kemdent, UK). All experiments were in accordance to the Animal (Scientific 
Procedures) Act 1986, UK, and were approved by the Local Ethical Review 
Committee at the University of Oxford and the Home Office of the United Kingdom. 
Behavioural testing  
Optogenetic stimulation. Green-light pulses were produced by a TTL-modulated 
DPSS laser (532 nm, CNI Lasers, China) using a computer-controlled pulse 
generator (Doric Lenses, Canada) and coupled to an optical fibre of 200µm diameter 
and 0.39 NA (Thorlabs) via an adjustable collimator (CNI). Implanted optic fibres 
were connected via zirconia sleeves (Thorlabs) to an optic fibre cable attached via a 
commutator (Doric Lenses, Canada). For all optogenetic stimulations, 5 ms light 
pulses (power 2.0 – 5 mW, wavelength 532 nm) were delivered unilaterally at a 
frequency of 20 Hz for episodes of 5 s, alternating with 5 s pauses. Stimulation was 
given for either 1 min (Y-maze, ITI-phase), 2 min (Y-maze, test-phase), 3 min (all 
stimulations in the open field, Y-maze ITI+test-phase stimulation, elevated plus-
maze) or 5 min (all remaining behavioural tests).  Stimulation-sequences were 
delivered once per day, with a minimum 2 day recovery time for each hemisphere 
before subsequent stimulations. This was necessary as repeated stimulations with 
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shorter intervals could increase the risk of inducing seizures in some animals. 
Animals experiencing optogenetically-induced seizures were not used in subsequent 
experiments and data from the experiment in which a seizure was observed were not 
included in any analyses. Optical power at the ferrule connected to the implanted 
optic fibre was measured before and after testing of each animal. Data for individual 
tests were excluded for Chronos-transfected animals if the power measured at the 
end of testing was more than 0.5 mW lower than the level determined during 
calibration (next section).  
Optogenetically-induced hyperlocomotion. Mice of both groups were first 
optogenetically stimulated unilaterally for 3 min, starting at minute 15 of a 30 min 
exploration of an open field  (l 43 cm, w 22 cm, h 20 cm; San Diego Instruments), 
and the number of infrared beam breaks was used as a locomotor activity readout. 
Starting at 2 mW, optical power was increased in 0.5 mW increments, and locomotor 
activity during optogenetic stimulation was measured; different hemispheres were 
tested on consecutive days. Calibration was terminated when hyperlocomotion of > 
115 % of baseline (an average of the preceding 9 min baseline period) was observed 
twice at the same stimulation power in the same hemisphere in Chronos animals. 
The optimal power to be used in all subsequent experiments was determined for 
each animal individually from this calibration (LH: n = 7, RH: n = 11). GFP-
transfected animals (controls) experienced a similar “calibration” alongside Chronos-
transfected animals, to ensure comparable prior experience and control for non-
specific effects of illumination. Power levels and the hemisphere receiving stimulation 
in control animals were matched to the Chronos group where possible. In cases 
where there were more GFP than Chronos animals, the power for the additional 
animals was set to intermediate values to ensure the same mean power in both 
groups. Unilateral stimulation, and the calibration of optical power for each animal 
was necessary to exclude animals displaying optogenetically-induced seizures, 
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which we found were likely due to strong offsite expression in the dentate gyrus 
and/or CA3. To experimentally test the effects of optogenetic stimulation on 
locomotor activity, this procedure was repeated in a novel open field (40 x 40 cm, 25 
cm wall height). Distance moved was measured in 3-minute bins via video-tracking 
(AnyMaze, San Diego Instruments, CA, USA). On a later occasion, the experiment 
was repeated twice in that same open field 1 h after injection of either 1 mg/kg of the 
D2-receptor antagonist raclopride (10 µl/g, i.p; Sigma-Aldrich, UK) or vehicle (saline; 
within-subject design). The order of drug exposure (raclopride/vehicle) was 
counterbalanced and there were three days between each test.  
Effects of optogenetic stimulation on spatial novelty preference (SNP). We 
assessed hippocampus-dependent short-term memory using the SNP Y-Maze task45. 
This task involves familiarizing animals with part of an environment, and then 
allowing exploration of both the familiar part of the environment and a novel area 
(see Fig. 2a). Due to rodents’ innate preference to explore novel spaces, animals 
should preferentially explore the novel area during the test phase 45,65. For the SNP-
test with optogenetic stimulation, mice were tethered to the optical fibre and left to 
acclimatize to a novel holding cage for 5 min before testing. They were then 
transferred to a transparent Y-shaped maze, filled with sawdust for 5 min, in which 1 
of the 2 goal arms was blocked (sample phase). After a 1 min intra-trial interval (ITI) 
in the holding cage, mice were returned to the Y-maze for a 2 min test phase, in 
which both goal arms were accessible. Distance moved and time spent in each arm 
was measured via video-tracking (AnyMaze, San Diego Instruments, CA, USA). Mice 
were tested 4 times, in the same apparatus, but located in different rooms, and 
stimulation was applied during different stages of the task; either during 1) the 
sample phase 2) the ITI, 3) the test, or 4) throughout both the ITI and test phases 
(see Fig. 2a). To avoid the risk of overstimulation, sample-phase stimulation (5 min) 
was run last for all animals, and we did not stimulate throughout both the sample and 
 
 
21
test phases in the same trial. Locomotor data represent distance travelled in all 
available portions of the maze (i.e. all 3 arms in the test phase, familiar and start arm 
in the sample phase), unless stated otherwise.  
Effects of amphetamine on SNP and locomotion. For pharmacological 
experiments, the same protocol was followed except that mice were injected with 
either amphetamine or saline-vehicle 30 min before testing (2.5 mg/kg, i.p; between-
subject design) and placed in their home cage until 10 min before the sample phase 
when they were transferred to a novel holding cage (as above, Fig. 4a). A separate 
cohort of male wildtype mice was used (C57BL/6J, Charles Rivers; n = 12 
amphetamine treated, n = 11 vehicle). 
Effects of optogenetic stimulation on anxiety in the elevated plus maze (EPM). 
Animals were tested on an EPM (72 cm above ground) with two opposite grey closed 
arms (w 7 cm, l 38 cm, h 21 cm), and two open white arms (w 7cm, l 38 cm). After 
tethering, mice had a 5 min acclimation period in a novel cage and optogenetic 
stimulation began in the last 20-30 s of this phase (see Fig. 3a). Mice were then 
placed in the centre of the EPM facing an open arm, and left to explore for 5 min, 
with optogenetic stimulation continuing for the first 2.5 min of testing (total stimulation 
time = 3 min). Distance moved was measured via video tracking (AnyMaze, San 
Diego Instruments, CA, USA), and time spent in each arm was scored manually 
offline, blind to experimental group. Data presented are from the first 2.5 min of the 
test (during optogenetic stimulation). 
Effects of optogenetic stimulation on place preference (PP). To test whether 
stimulation during the Y-Maze task was sufficient to induce a PP within the time-
scale of minutes, we adapted the Y-Maze test to resemble a conditioned PP 
paradigm (see Fig. 3d). The start arm was blocked throughout, leaving accessible a 
V-shaped maze with two goal arms and a centre zone with removable doors for each 
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arm. Animals were tethered throughout testing and were always introduced into the 
maze centre-zone with both doors closed. Animals went through two sample phases 
of 5 min, separated by a short ITI of 30-60 s, and received 5 min optogenetic 
stimulation during the second sample phase. In each sample phase only one arm 
was accessible (e.g. the left arm in the first phase and the right arm in the second 
phase, or vice versa). Animals were then placed in a holding cage for a 1 min ITI 
before being placed back into the maze. Both doors were removed, and mice were 
allowed to explore the entire maze for 2 min (test phase). Counterbalancing the order 
of stimulation was not possible given that the effects of stimulation on locomotion 
were found to last beyond the stimulation period in previous tests (see Fig. 1b, c), 
and might therefore carry-over to the time in the ‘non-stimulated’ arm given the short 
delays used here.  
Animals were tested in a long-term PP task conducted in a modified 3–chamber 
apparatus (two 22 cm x 30 cm chambers joined by a 10cm x 20cm alley) over 3 days 
(see Fig. 3g). On day 1, animals were tethered (but not stimulated), placed in the 
central alley, and the sliding doors to both chambers were opened allowing 
exploration of the whole apparatus for 10 min. On day 2, animals began in the central 
alley and the door to one of the side compartments (left or right, counterbalanced) 
was opened. Once the animal entered the compartment the door was closed and the 
animal was left to explore for 5 min. For half the animals this first sample phase was 
paired with optogenetic stimulation. After a 2 h delay, animals were given a second 
sample phase (5 min) in the opposite chamber. Optogenetic stimulation was applied 
during the second sample phase for animals that did not receive it during the first 
sample. The following day, animals were placed in the central alley and both doors 
were opened to allow exploration of both chambers for 10 min. Animals were 
tethered for all phases of testing. Distance moved and time spent in each 
 
 
23
compartment were measured via video tracking (AnyMaze, San Diego Instruments, 
CA, USA). Only data for the first 5 min of the test phase are presented here. 
Histology  
Animals were euthanized with sodium pentobarbital (Euthatal) and perfused 
transcardially with PBS followed by 4% paraformaldehyde (PFA). Head caps with 
optic fibres were detached carefully and the brains were removed and fixed in PFA 
and then transferred to phosphate buffered saline (PBS). Coronal slices (60 μm) 
were cut on a vibratome (Leica), washed in PBS, then PBS containing 4',6-
diamidino-2-phenylindole (DAPI, 1: 1,000,000, Sigma) for 10 minutes. Slices were 
washed with PBS before mounting with Vectashield (Vector Labs, USA). Slices were 
scanned with a fluorescence microscope (Axio Zoom, Carl Zeiss) to detect DAPI and 
Chronos-GFP fluorescence. 
Analysis 
Data were tested for normality using the Shapiro-Wilks Test. Where data for both 
groups was normally distributed, parametric tests (t-test or ANOVA) were applied, 
otherwise non-parametric equivalents were used. A 3-way repeated-measures 
ANOVA was used for the raclopride experiment despite data for some conditions not 
being normally distributed; however pairwise comparisons using appropriate non-
parametric tests (not presented) yielded the same pattern of statistical significance. 
For t-test analyses, the adjusted t-values and df’s are reported for instances where 
Levene’s test for equality of variances indicated significant differences. In all cases, 
parametric and non-parametric tests yielded similar results. 
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Data availability 
All data generated or analysed during this study are included in this article. All 
numeric source data for the presented figures are available from the corresponding 
author on reasonable request at the desired level of analysis. 
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FIGURE CAPTIONS 
Figure 1. Optogenetic activation of the vHPC induces hyperlocomotion. (a) 
Selective transfection of the vHPC (vSUB & vCA1) is indicated by GFP-fluorescence 
(left) derived from the transfected Chronos-GFP expression cassette. Blue 
background stain with DAPI. Note that the dorsal fluorescence is autofluorescence 
from damage to the tissue, rather than Chronos-GFP expression. Photomicrograph 
of the location of vertically implanted optic fibre coated in DiI (red) 100-200 µm above 
the pyramidal cell layer of the vHPC (right; DiI was not applied in experimental 
animals). (b) High-resolution image to illustrate the membrane-bound expression of 
Chronos-GFP (green) in the somata (vSUB PC-s) and dendrites (vSUB PC-d) of 
pyramidal cells of the vSUB. Scale bar = 100 µm; blue, DAPI stain; the ventral pole is 
left, the dorsal pole right. This image is from a separate animal not used for 
behavioural testing. (c) Optogenetic induction of hyperlocomotion during stimulation 
(block starting at minute 15; green shaded area) in the pre-screened cohort in a 
novel open field. Inset (top right) shows locomotion calculated for each min of the 3 
min stimulation as a % of baseline (min 15-18). (d) Data of (c) expressed as distance 
moved during the stimulation-phase (during-stim; green shading), and the first post-
stimulation block (post-stim) as a percentage of the average distance moved during 
baseline (3 blocks immediately before stimulation; grey shading). (e, f) Same 
experiment as in Fig. 1c, with injection of vehicle (Veh; grey) or the D2R antagonist 
raclopride (Rac; 1 mg/kg; blue) 1 h before the start of the experiment. Optogenetic 
stimulation in minutes 15-18 (green shading), with baseline period shown in grey 
shading. (f) Locomotion during optogenetic stimulation of the vHPC (stimulation as % 
of baseline) following vehicle (grey) or Raclopride (blue) injection. (g-i) Absolute 
changes in locomotion from baseline to stimulation phase are shown separately for 
the GFP controls (g) and Chronos animals (h), and for both groups following 
Raclopride injection (i). Indication of significant effects or interactions are omitted 
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from (c, e, f, and g-i) for clarity, see main text for analysis. Data are shown as mean ± 
SEM; * p < 0.05, ** p < 0.01, Kolmogorov-Smirnov Z Test. Abbreviations, DG: 
dentate gyrus; DG MoL, molecular layer of the DG; CA1: cornu ammonis area 1; 
vSUB: ventral subiculum; APir: amygdalopiriform transition area; VIEnt: ventral 
intermediate entorhinal cortex; AHiPM: amygdalohippocampal area, posteromedial 
part; PMCo: posteromedial cortical amygdaloid area. 
 
Figure 2. Optogenetic impairment of spatial novelty preference (SNP). (a) 
Illustration of the Y-maze test protocol used to assess SNP. In all cases animals 
were familiarized to a novel cage and the tether before introduction into the Y-maze 
(acclimation). Green dashed lines above indicate the phase of optogenetic 
stimulation for the 4 different stimulation phases used: 1) sample phase (Sample) 2) 
Intra-trial interval (ITI) 3) test phase (Test) and 4) ITI and test phase (ITI + Test). (b) 
Example path lengths from individual GFP (left) and Chronos animals (right) are 
shown for exploration during the test phase following stimulation in the sample phase 
(top) or the ITI+Test phase (bottom). The novel arm is indicated by the arrow. (c) 
Optogenetically-induced hyperlocomotion was observed during stimulation for each 
stimulation phase during which locomotion was recorded; locomotion was not 
tracked in the holding cage, and is therefore not shown for the ITI only stimulation 
condition, and data for ITI+Test stimulation are shown for the test phase only. (d, e) 
Preference ratios for the novel arm calculated as the ratio of the time spent in the 
novel goal arm to the time spent in both goal arms. Data are presented averaged 
across all 4 stimulation phases (reflecting the main effect of group from the ANOVA; 
d) or individually for each stimulation protocol (e). The dashed lines (d-e) indicate 
chance level (0.5), i.e. equal preference for both goal arms. Data are shown as mean 
± SEM; * p < 0.05, *** p < 0.001; t-Test or Kolmogorov-Smirnov Z-Test.  
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Figure 3. Optogenetic activation of the vHPC does not alter anxiety or place 
preference. (a) Experimental paradigm used to assess anxiety following optogenetic 
stimulation (green), with bold lines indicating walled arms of the elevated plus-maze 
(EPM) apparatus. Locomotion (b) and preference for the open arm (c) on the EPM. 
Data are presented for the first half (2.5 min) of the test on the EPM (when 
optogenetic stimulation was applied). Preference for the open arms was measured 
as the percentage of time spent in the open arms relative to time spent in all open 
and closed arms. (d) Experimental paradigm for testing short-term place preference 
(PP) in the modified Y-Maze apparatus, delivery of optogenetic stimulation is shown 
in green. (e) Locomotor activity in the individual phases of the test: first sample 
phase, with no stimulation (No Stim); second sample phase, with stimulation (Stim); 
and test phase (Test). (f) Preference ratio measured as time spent in the goal arm of 
the Y-maze in which optogenetic stimulation was delivered relative to time in both 
goal arms. Dashed line indicates chance performance (i.e. equal preference for both 
goal arms). (g) Experimental paradigm for testing long-term place preference in a 
modified 3-chamber apparatus. (h) Locomotion during different phases of test. (i) 
Preference ratios for time spent in the chamber of the apparatus in which stimulation 
was applied during the test phase conducted 24 h later. Dashed line indicates 
chance performance (i.e. equal preference for both goal arms). * p < 0.05, ** p < 
0.01; t-Test or Kolmogorov-Smirnov Z-Test. Data are shown as mean ± SEM. 
 
Figure 4. Increased dopamine is not sufficient to induce impairments in spatial 
novelty preference. (a) Experimental paradigm for assessing the effects of the 
dopamine agonist amphetamine (2.5 mg/kg; Amph) administered 30 min before 
testing on (b) hyperlocomotion and (c) novelty preference. (b) Amphetamine 
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administration in wild type mice produced hyperlocomotion relative to vehicle-treated 
controls (Veh) during both the sample and test phases of the SNP task. (c) Novelty 
preference ratios for the time spent in the novel arm relative to the time spent in both 
goal arms combined did not differ between Amph and Veh injected mice, and 
performance in both groups was above chance level (Dashed line = 0.5; i.e. equal 
preference for both goal arms). ***  = p < 0.001, t-Test.  
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